Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2015 1
2019 1
2020 2
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.
Elía A, Saldain L, Vanzulli SI, Helguero LA, Lamb CA, Fabris V, Pataccini G, Martínez-Vazquez P, Burruchaga J, Caillet-Bois I, Spengler E, Acosta Haab G, Liguori M, Castets A, Lovisi S, Abascal MF, Novaro V, Sánchez J, Muñoz J, Belizán JM, Abba MC, Gass H, Rojas P, Lanari C. Elía A, et al. Among authors: pataccini g. Clin Cancer Res. 2023 Mar 1;29(5):866-877. doi: 10.1158/1078-0432.CCR-22-2060. Clin Cancer Res. 2023. PMID: 36269797 Free PMC article.
Antiprogestins for breast cancer treatment: We are almost ready.
Elia A, Pataccini G, Saldain L, Ambrosio L, Lanari C, Rojas P. Elia A, et al. Among authors: pataccini g. J Steroid Biochem Mol Biol. 2024 Mar 28;241:106515. doi: 10.1016/j.jsbmb.2024.106515. Online ahead of print. J Steroid Biochem Mol Biol. 2024. PMID: 38554981
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
Abascal MF, Elia A, Alvarez M, Pataccini G, Sequeira G, Riggio M, Figueroa V, Lamb CA, Rojas PA, Spengler E, Martínez-Vazquez P, Burruchaga J, Liguori M, Sahores A, Wargon V, Molinolo A, Hewitt S, Lombes M, Sartorius C, Vanzulli SI, Giulianelli S, Lanari C. Abascal MF, et al. Among authors: pataccini g. Int J Cancer. 2022 May 1;150(9):1481-1496. doi: 10.1002/ijc.33913. Epub 2022 Jan 13. Int J Cancer. 2022. PMID: 34935137 Free article.
Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity.
Sequeira GR, Sahores A, Dalotto-Moreno T, Perrotta RM, Pataccini G, Vanzulli SI, Polo ML, Radisky DC, Sartorius CA, Novaro V, Lamb CA, Rabinovich GA, Salatino M, Lanari C. Sequeira GR, et al. Among authors: pataccini g. Cancer Res. 2021 Mar 1;81(5):1375-1387. doi: 10.1158/0008-5472.CAN-20-1441. Epub 2020 Dec 2. Cancer Res. 2021. PMID: 33268529
FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
Giulianelli S, Riggio M, Guillardoy T, Pérez Piñero C, Gorostiaga MA, Sequeira G, Pataccini G, Abascal MF, Toledo MF, Jacobsen BM, Guerreiro AC, Barros A, Novaro V, Monteiro FL, Amado F, Gass H, Abba M, Helguero LA, Lanari C. Giulianelli S, et al. Among authors: pataccini g. Int J Cancer. 2019 Oct 1;145(7):1874-1888. doi: 10.1002/ijc.32252. Epub 2019 Mar 28. Int J Cancer. 2019. PMID: 30843188 Free article.